Daratumumab,Talquetamab,Teclistamab,Pomalidomide
Genmab,Janssen
['paradigm', 'multiple myeloma', 'mmsm']
bhagirathbhai dholaria, mbbs, noted that bispecific monoclonal antibodies may become an important part of the relapsed/refractory multiple myeloma treatment paradigm. #mmsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.